Algum conteúdo deste aplicativo está indisponível no momento.
Se esta situação persistir, por favor entre em contato conoscoFale conosco & Contato
1. (GB2531093) Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
Nota: O texto foi obtido por processos automáticos de reconhecimento ótico de caracteres.
Para fins jurídicos, favor utilizar a versão PDF.
CLAIMS
1.         Cannabidiol (CBD) for use in the treatment of epilepsy, wherein the epilepsy is a
treatment-resistant epilepsy (TRE), and wherein the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 50% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
2.         CBD for use according to claim 1, wherein the CBD is used in combination with two or more concomitant anti-epileptic drugs (AED).
3.         CBD for use according to claim 1 or claim 2, wherein the type of treatment-resistant epilepsy is Dravet syndrome, myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES).
4.         CBD for use according to claim 3, wherein the seizure type to be treated is a complex partial seizure (focal seizure with impairment).
5.         CBD for use according to any of the preceding claims, wherein the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 70% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
6.         CBD for use according to any of the preceding claims, wherein the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 90% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
7.         CBD for use according to any of the preceding claims, wherein the CBD is present in an amount that reduces total convulsive seizure frequency by 100% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
8.         CBD for use according to any of the preceding claims, wherein the CBD is present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD.
9.         CBD for use according to claim 2, wherein the one or more AED is selected from the group consisting of: clobazam; levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; zonisamide; perampanel; and fosphenytoin.
10.       CBD for use according to claim 9, wherein one of the AED is clobazam.
11.       CBD for use according to any of the preceding claims, wherein the number of different anti-epileptic drugs that are used in combination with the CBD is reduced.
CBD for use according to any of the preceding claims, wherein the dose of anti-epileptic drugs that are used in combination with the CBD is reduced.
CBD  for use according claim 11 , wherein the dose of AED which is reduced is of clobazam.
CBD  for use according to any of the preceding claims, wherein the dose of CBD is from 5 mg/kg/day to 25 mg/kg/day.
A  method of treating treatment-resistant epilepsy comprising administering cannabidiol (CBD) to a patient in an amount sufficient to reduce total convulsive seizure frequency by greater than 50% with respect to the seizure frequency achieved on one or more concomitant anti-epileptic drugs (AED).